Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

  1. Hurvitz, S.A.
  2. Bardia, A.
  3. Quiroga, V.
  4. Park, Y.H.
  5. Blancas, I.
  6. Alonso-Romero, J.L.
  7. Vasiliev, A.
  8. Adamchuk, H.
  9. Salgado, M.
  10. Yardley, D.A.
  11. Berzoy, O.
  12. Zamora-Auñón, P.
  13. Chan, D.
  14. Spera, G.
  15. Xue, C.
  16. Ferreira, E.
  17. Badovinac Crnjevic, T.
  18. Pérez-Moreno, P.D.
  19. López-Valverde, V.
  20. Steinseifer, J.
  21. Fernando, T.M.
  22. Moore, H.M.
  23. Fasching, P.A.
Revue:
The Lancet Oncology

ISSN: 1474-5488,  1470-2045

Année de publication: 2023

Volumen: 24

Número: 9

Pages: 1029-1041

Type: Article

DOI: 10.1016/S1470-2045(23)00268-1 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus